France Antirheumatic drugs market was valued at US$1,095.785 million in 2019. The antirheumatic drugs market in France is poised to grow on account of the high government support in the country for providing better healthcare services to the citizens along with the presence of a well-established healthcare sector of the country. The majority of the health expenditure of the country is government-funded which further enables the citizens to afford costly treatments and medicines which is also one of the key factors bolstering the market growth in the country. Around 79% of total health expenditure is funded by the government on account of growing concerns regarding the burden of rising out-of-pocket expenditure, particularly among people without any good complementary health insurance.
Furthermore, the growing geriatric population is also one of the prime factors driving the demand for these drugs as people in old age are more inclined towards these types of diseases. Also, the government funding regarding healthcare also provides support to the people in their old age to pay for costly medicines and treatments, thus positively impacting the market growth during the next five years. The population ages 65 and above reached 13,418,612 by 2018 from 10,623,736 in 2008.
France antirheumatic drugs market has been segmented on the basis of the type of disease, type of molecule, and sales channel. On the basis of the type of disease, the market has been classified on the basis of osteoarthritis, rheumatoid arthritis, gout, lupus, and others.By the type of molecule, the market has been segmented on the basis of pharmaceuticals and biopharmaceuticals. By the sales channel, the segmentation has been done on the basis of prescription and over-the-counter (OTC).